Web Exclusives
Web Exclusives | March 15, 2023
Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
Web Exclusives | March 15, 2023
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
Web Exclusives | March 15, 2023
Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.
Web Exclusives | March 15, 2023
Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.
Web Exclusives | February 21, 2023
A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Web Exclusives | February 21, 2023
Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.
Web Exclusives | January 26, 2023
Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.
Web Exclusives | January 26, 2023
In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.
Web Exclusives | January 26, 2023
Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.
Web Exclusives | January 26, 2023
A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.
Web Exclusives | December 5, 2022
A guide to the departments and people you should be working with to collect the data pertinent to your navigation program.
Web Exclusives | December 5, 2022
Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.
Web Exclusives | December 2, 2022
Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.
Web Exclusives | December 2, 2022
Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.
Web Exclusives | December 2, 2022
All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.
Web Exclusives | December 2, 2022
In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.
Web Exclusives | November 2, 2022
In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment.
Web Exclusives | November 2, 2022
CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation.
Web Exclusives | November 2, 2022
Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low.
Web Exclusives | November 2, 2022
Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups.
Web Exclusives | November 2, 2022
Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations.
Web Exclusives | October 14, 2022
A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated.
Web Exclusives | October 14, 2022
Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer.
Web Exclusives | October 14, 2022
Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy.
Web Exclusives | October 14, 2022
Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans.
Web Exclusives | September 26, 2022
When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion.
Web Exclusives | September 26, 2022
Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival.
Web Exclusives | September 26, 2022
Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity.
© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512